and oteracil potassium (Oxo), in a molar ratio of 1.0 : 0.4 : 1.0 [1] . The combination of CDHP with tegafur facilitates prolonged, higher 5-fl uorouracil (5-FU) concentrations in blood and tumors. Oxo specifi cally inhibits the phosphoribosylation of 5-FU, leading to suppression of gastrointestinal toxicity [2] . In two phase II studies, S-1 exhibited high effi cacy and tolerable safety in patients with previously untreated advanced gastric cancer (AGC). The pooled response rate, 1-and 2-year survival rates, and median survival time in the two studies (101 patients in total) were 45%, 37%, 17%, and 8.1 months, respectively. Furthermore, grade 3 or 4 drug-related adverse reactions remained at low incidences of between 2% and 10% [3, 4] . In Japan, S-1 is currently being investigated as one of the key drugs for AGC, promising state-of-the-art treatment. It also offers the potential of broader use for other carcinomas, including colorectal, head and neck, lung, breast, and pancreatic cancers. The effi cacy and safety of S-1 monotherapy demonstrated in the phase II studies of AGC were also reproducible for these carcinomas [5] [6] [7] [8] [9] [10] . S-1 is thus considered likely to play a crucial role in the treatment of several advanced cancers.
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The clinical use of S-1 in practice began with a postmarketing survey by the manufacturer in 1999 (Taiho Pharmaceuticals, Tokyo, Japan) [11] . The survey was prospectively conducted with the primary aim of collecting as wide a range of safety information as possible. Approximately 4000 patients were eventually enrolled, and the survey certainly promises to reveal comprehensive safety profi le data on S-1. A previous article has already reported that the overall incidence of adverse drug reactions during the fi rst two cycles in the survey were 74% for all grade events and 25% for grade 3 or 4 events; the tolerable safety of S-1 in the phase II studies was confi rmed in a large population [11] .
In this article, we use the data from the same survey and aim to identify risk factors associated with the oc-Introduction S-1 is a novel oral fl uoropyrimidine consisting of tegafur and two biochemical modulators, gimeracil (CDHP) currence of grade 3 or 4 adverse events. Specifi cally, we focus on the events in the fi rst two cycles. This is because most of the fi rst occurrence of grade 3 or 4 events was observed during this period; more than 70% of hematological events were experienced during the fi rst and second cycles, and the same holds true for most of the nonhematological events. Adverse events experienced during the early period have clinically important implications because they lead to a decline in patient compliance with the drug in subsequent treatment cycles. Thus, as for S-1, adverse events during the early period are of particular signifi cance; thus, as in the previous article [11] , we focus here on grade 3 or 4 events in the fi rst two cycles.
Methods

Patients
From March 1999 through March 2000, all of patients scheduled for administration of S-1 were registered in the survey. It was prospectively conducted by the manufacturer to comply with the regulatory requirement for the collection of as much safety profi le data as possible during the early postmarketing period of the drug. All the registered patients gave informed consent before enrollment and received S-1 as a single-agent therapy. Central registration and data collection and management were performed to ensure data quality [11] .
Treatment delivery
The initial dosages of S-1 were assigned on the basis of body surface area (BSA), and the patients received one of the following oral dosages twice daily after meals: 40 mg for patients with BSA <1.25 m 2 , 50 mg for BSA ≥1.25 and <1.50 m 2 , and 60 mg for BSA ≥1.50 m 2 . One cycle of the therapy comprised the administration of single agent S-1 for 28 consecutive days followed by 14 days of no treatment. This schedule was repeated every 6 weeks until the occurrence of disease progression, unacceptable toxicities, or patient refusal. Dose modifi cation followed the schedule used in the previous studies [3, 4] .
Assessment of safety
Adverse events were assessed and graded 1 to 4 according to the criteria of the Japan Society of Clinical Oncology, which is the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 1 [12] with a few minor modifi cations adapted to Japanese patients [13] . To confi rm the results of laboratory tests and the occurrence of adverse events, onsite monitoring visit was conducted once a week during the fi rst cycle and twice a month thereafter.
Statistical methods
Statistical analysis for the association between clinical variables and severe adverse events was conducted as follows. For each adverse event, the univariate Fisher's exact test was used to screen out possible associated factors from available clinical variables. From these screened factors, a backward stepwise logistic regression method was then used to determine the risk factors [14] . All the variable selection procedures were based on a two-tailed statistical signifi cance level of 5%. All P values were reported as two-tailed and calculated using SAS for Windows (SAS Institute, Cary, NC, USA).
Results
Patient population
A total of 4177 patients were registered from 757 institutions in Japan. Of these, 3758 were AGC patients and used for our analysis. The data from the other 419 patients were excluded owing to no administration of S-1 or malignancies other than AGC. The demographics of the patients are summarized in Table 1 . They closely resembled those of patients in the previous phase II studies [3, 4] .
Risk factors for grade 3 or 4 adverse events
The initial candidate variables were age, sex, body mass index, performance status, liver metastasis, disease status (inoperable, recurrent, or residual), chemotherapy within the 6 months prior to starting S-1, baseline complications, and basic laboratory test parameters (hemoglobin, leukocyte count, neutrophil count, platelet count, total bilirubin, serum aspartate aminotransferase, serum alanine aminotransferase, and serum creatinine). Table 2 summarizes the risk factors, which were determined from among these variables, for some of the key adverse events of S-1: neutropenia, decrease in hemoglobin, nausea/vomiting, anorexia, and hyperbilirubinemia. Neutropenia was associated with creatinine clearance calculated using the Cockcroft and Gault equation [15] . For each range of creatinine clearance (ml/min) (50-79, 30-49, and <30), the odds ratios (ORs) in reference to the range >80 were estimated to be 1.21 (P = 0.238), 1.79 (P = 0.005), and 2.43 (P = 0.107), respectively (Table 2) , where creatinine clearance was categorized according to previous reports [16, 17] . It is particularly important that the patients with an impaired baseline renal function of creatinine clearance <30 ml/ min had a more than two-fold risk compared to normal patients, although this was not statistically signifi cant due to small sample size in this category (38/3758 patients). Some severe adverse events, such as decrease in hemoglobin, nausea/vomiting, thrombocytopenia, anorexia, and fatigue, naturally depended on baseline symptoms (with baseline symptom versus no symptom: OR = 5.05, P < 0.001 for hemoglobin decrease; OR = 3.59, P < 0.001 for nausea/vomiting; OR = 3.62, P < 0.001 for anorexia; OR = 7.85, P < 0.001 for thrombocytopenia; OR = 5.70, P < 0.001 for fatigue). It was also found that treatment history with some anticancer agents may possibly have an effect on the appearance of adverse effects. Hemoglobin decrease, nausea/vomiting, and hyperbilirubinemia were founded to be affected by the previous use of irinotecan (OR = 3.07, P = 0.003), mitomycin (OR = 2.28, P = 0.004), and cisplatin (OR = 1.60, P = 0.007) ( Table 2 ). For other key gastrointestinal events including diarrhea and stomatitis, which are typical adverse effects associated with fl uoropyrimidine, no risk factors were identifi ed in our analysis at the 5% level of signifi cance. Thus, factors other than those considered here, possibly molecular ones, might be associated with the occurrence of severe diarrhea or stomatitis. Table 3 shows the estimated incidence probabilities of severe neutropenia, nausea/vomiting, and hyperbilirubinemia, which can be obtained from the odds ratios in the logistic regression models in Table 2 . It is observed that the incidence probability of neutropenia has a wide range, depending on the initial status of creatinine clearance and baseline neutrophil count. For patients with a normal condition (creatinine clearance ≥80 ml/min and neutrophil count ≥2000/mm 3 ), the estimated incidence probability remains at 5.0%; whereas it rises to 33.7% for patients with an impaired baseline condition of creatinine clearance <30 ml/min and a neutrophil count <2000/mm 3 . Similarly, the incidence probability of nausea/vomiting ranges from 1.5% to 47.8% depending on initial performance status, nausea/vomiting at baseline, and a history of mitomycin use. Hyperbilirubinemia ranges from 1.8% to 23.6% depending on initial status of liver metastasis, baseline platelet count, and a history of cisplatin use. The incidence probabilities of other adverse events can be estimated similarly.
Discussion
After approval was obtained in Japan, the clinical use of S-1 had been monitored for 1 year in a prospectively registered survey by the manufacturer. Since the survey was conducted in the context of medical practice, it included a certain number of patients who are generally excluded from premarketing clinical trials, such as those with peritoneal dissemination. For AGC, there is often no direct comparison of safety profi les between phase II studies and general use due primarily to the exclusion of such patients. The current survey was conducted as a census with the registration of all the patients treated with S-1; therefore, it should assist in bridging the gap, as it provides a comprehensive safety profi le [11] .
The purpose of this study was to describe the attempts to capture the potential risk factors for severe adverse events of S-1. Myelosuppression (neutropenia, hemoglobin decrease, or thrombocytopenia) was the dose-limiting toxicity in the phase I study [18] and recognized as one of the key adverse effects of S-1. As expected, the baseline neutrophil count, hemoglobin level, or platelet count was a risk factor for events at the grade 3 or 4 level. In addition, the baseline renal function was found to affect signifi cantly the occurrence of severe neutropenia. Consequently, the estimated inci- dence of neutropenia remained at only 5.0% for patients with a normal neutrophil count and a normal renal function at baseline, whereas it increased drastically up to 33.7% for patients whose status for these two features differed from normal. Other severe adverse events, including anorexia and fatigue, were also highly related to the baseline condition, which implies the importance of patient selection before commencing S-1 administration. Nausea/vomiting (a key gastrointestinal adverse effect of fl uoropyrimidine decreasing patients' quality of life), anorexia (one of the most frequent adverse events of S-1), and thrombocytopenia were infl uenced to a great extent by the baseline performance status (PS). Notably, patients with PS = 1 were shown to have a statistically signifi cant higher risk of nausea/vomiting, anorexia, or thrombocytopenia than those with PS = 0 (nausea/vomiting: OR = 1.54, P = 0.025; anorexia: OR = 1.51, P < 0.001; thrombocytopenia: OR = 1.77, P = 0.019).
Another result from our analysis to be taken into consideration when assessing the safety of S-1 is that the previous use of some chemotherapeutic drugs may be implicated in the experience of severe adverse events. The analysis suggested that use of some chemotherapeutic agents prior to the start of S-1 treatment might affect outcomes, such as nausea/vomiting, hemoglobin decrease, and hyperbilirubinemia. Although the possible mechanisms for the effects caused by these drugs are not clear, more caution is in order for the patients who having been treated with such drugs.
The current postmarketing survey was conducted under a well-organized scheme and provided us with an opportunity to evaluate not only reliable incidence rates but the risk factors for severe adverse outcomes. The survey has demonstrated the tolerable toxicity of S-1 among the nearly 4000 patients, affi rming the results of the phase II studies and thus providing a sound basis for the safe use of S-1. Our analysis has effectively enabled the identifi cation of patient subgroups potentially at higher risk with S-1 administration, thus is expected to be conducive to the drug's safer administration and to establish requirements for new therapy options. The insight gained from postmarketing surveys should help us understand many of the safety facets of chemotherapeutic agents as well as facilitate reevaluation of the results obtained in premarketing clinical trials. Active involvement in postmarketing surveys would contribute to facilitating safer administration of drugs. a Use history within 6 months prior to start of S-1 treatment
